keyword
MENU ▼
Read by QxMD icon Read
search

Her 2 positive Breast cancer

keyword
https://www.readbyqxmd.com/read/28335434/induction-of-g2m-arrest-by-flavokawain-a-a-kava-chalcone-increases-the-responsiveness-of-her2-overexpressing-breast-cancer-cells-to-herceptin
#1
Danielle D Jandial, Lauren S Krill, Lixia Chen, Chunli Wu, Yu Ke, Jun Xie, Bang H Hoang, Xiaolin Zi
HER2/neu positive breast tumors predict a high mortality and comprise 25%-30% of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces the viabilities of HER2-overexpressing breast cancer cell lines (i.e., SKBR3 and MCF7/HER2) versus those with less HER2 expression (i.e., MCF7 and MDA-MB-468). FKA at cytotoxic concentrations to breast cancer cell lines also has a minimal effect on the growth of non-malignant breast epithelial MCF10A cells. FKA induces G2M arrest in cell cycle progression of HER2-overexpressing breast cancer cell lines through inhibition of Cdc2 and Cdc25C phosphorylation and downregulation of expression of Myt1 and Wee1 leading to increased Cdc2 kinase activities...
March 14, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28319069/the-branched-chain-amino-acid-transaminase-1-sustains-growth-of-antiestrogen-resistant-and-er%C3%AE-negative-breast-cancer
#2
V Thewes, R Simon, M Hlevnjak, M Schlotter, P Schroeter, K Schmidt, Y Wu, T Anzeneder, W Wang, P Windisch, M Kirchgäßner, N Melling, N Kneisel, R Büttner, U Deuschle, H P Sinn, A Schneeweiss, S Heck, S Kaulfuss, H Hess-Stumpp, J G Okun, G Sauter, A E Lykkesfeldt, M Zapatka, B Radlwimmer, P Lichter, M Tönjes
Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and two fulvestrant resistant) MCF-7 breast cancer cell lines. The branched-chain amino acid transaminase 1 (BCAT1), which catalyzes the first step in the breakdown of branched-chain amino acids, was among the most upregulated transcripts in antiestrogen-resistant cells...
March 20, 2017: Oncogene
https://www.readbyqxmd.com/read/28288939/breast-cancer-resistance-protein-bcrp-abcg2-and-p-glycoprotein-p-gp-abcb1-transport-afatinib-and-restrict-its-oral-availability-and-brain-accumulation
#3
Stéphanie van Hoppe, Rolf W Sparidans, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel
Afatinib is a highly selective, irreversible inhibitor of EGFR and (HER)-2. It is orally administered for the treatment of patients with EGFR mutation-positive types of metastatic NSCLC. We investigated whether afatinib is a substrate for the multidrug efflux transporters ABCB1 and ABCG2 and whether these transporters influence oral availability and brain and other tissue accumulation of afatinib. We used in vitro transport assays to assess human (h)ABCB1-, hABCG2- or murine (m)Abcg2-mediated transport of afatinib...
March 10, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28285212/glycogen-rich-clear-cell-carcinoma-grcc-of-the-breast-may-not-have-a-poor-prognosis
#4
Muna M Baslaim, Enaam M Junainah, Hadeel H Ahmad, Anmar F Semilan, Ahmed O Al-Ghamdi, Noora O Rahimuddin, Budoor A Salman
INTRODUCTION: Glycogen Rich Clear Cell Carcinoma (GRCC) is a rare variant of breast carcinomas and believed to be linked with a poor prognosis. CASE SUMMARY: We are presenting a 60-year-old Saudi lady with a 2cm GRCC carcinoma associated with clear cell ductal carcinoma in situ (DCIS) and no axillary lymph node involvement. The tumor was Estrogen and Progesterone receptors (ER & PR) positive and HER 2-neu negative. She underwent mastectomy with sentinel lymph node biopsy followed by hormonal therapy...
February 27, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28270211/syndecan-1-is-a-novel-molecular-marker-for-triple-negative-inflammatory-breast-cancer-and-modulates-the-cancer-stem-cell-phenotype-via-the-il-6-stat3-notch-and-egfr-signaling-pathways
#5
Sherif Abdelaziz Ibrahim, Ramy Gadalla, Eslam A El-Ghonaimy, Omnia Samir, Hossam Taha Mohamed, Hebatallah Hassan, Burkhard Greve, Mohamed El-Shinawi, Mona Mostafa Mohamed, Martin Götte
BACKGROUND: Inflammatory breast cancer (IBC), a particularly aggressive form of breast cancer, is characterized by cancer stem cell (CSC) phenotype. Due to a lack of targeted therapies, the identification of molecular markers of IBC is of major importance. The heparan sulfate proteoglycan Syndecan-1 acts as a coreceptor for growth factors and chemokines, modulating inflammation, tumor progression, and cancer stemness, thus it may emerge as a molecular marker for IBC. METHODS: We characterized expression of Syndecan-1 and the CSC marker CD44, Notch-1 & -3 and EGFR in carcinoma tissues of triple negative IBC (n = 13) and non-IBC (n = 17) patients using qPCR and immunohistochemistry...
March 7, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28260828/differential-site-based-expression-of-pentose-phosphate-pathway-related-proteins-among-breast-cancer-metastases
#6
Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo
Purpose. We aimed to investigate the expression of pentose phosphate pathway- (PPP-) related proteins in metastatic breast cancer and its relationship with clinicopathologic factors. Methods. Tissue samples from 126 metastatic breast cancers were included in a tissue microarray. Expression of PPP-related proteins [glucose-6-phosphate dehydrogenase (G6PDH), 6-phosphogluconolactonase (6PGL), 6-phosphogluconate dehydrogenase (6PGDH), and nuclear factor erythroid 2-related factor (NRF2)] was determined by immunohistochemistry...
2017: Disease Markers
https://www.readbyqxmd.com/read/28253728/expression-of-dna-methylation-related-proteins-in-metastatic-breast-cancer
#7
Y J Cha, W H Jung, J S Koo
We aimed to investigate the expression of methylation related proteins (5-meC and DNMT1) in the metastatic breast cancers of variable sites and its association with clinicopathologic factors. A total of 126 metastatic breast cancers (31 bone metastases, 36 brain metastases, 11 liver metastases, 48 lung metastases) were made into tissue microarray and immunohistochemical staining of ER, PR, HER-2, Ki-67, 5-meC, and DNMT1 were performed. Molecular classification was made on the basis of immunohistochemical staining result of ER, PR, HER-2, Ki-67; luminal A, luminal B, HER-2, triple negative breast cancer (TNBC)...
March 3, 2017: Neoplasma
https://www.readbyqxmd.com/read/28253285/pten-expression-as-a-predictor-for-the-response-to-trastuzumab-based-therapy-in-her-2-overexpressing-metastatic-breast-cancer
#8
Daphne Gschwantler-Kaulich, Yen Y Tan, Eva-Maria Fuchs, Gernot Hudelist, Wolfgang J Köstler, Angelika Reiner, Carmen Leser, Mohamed Salama, Johannes Attems, Christine Deutschmann, Christoph C Zielinski, Christian F Singer
BACKGROUND: Even though trastuzumab is an effective therapy in early stage Her-2+ breast cancer, 40-50% of advanced Her-2+ breast cancer patients develop trastuzumab resistance. A potential resistance mechanism is aberrant downstream signal transmission due to loss of phosphatase and tensin homologue (PTEN). This study investigated the relationship between the expression of PTEN and trastuzumab response in Her-2 overexpressing metastatic breast cancer patients. METHODS: Between 2000 and 2007, 164 patients with Her-2+ metastatic breast cancer received trastuzumab-based therapy in our institution...
2017: PloS One
https://www.readbyqxmd.com/read/28248066/serum-dickkopf-1-act-as-a-new-biomarker-in-human-breast-cancer
#9
Jin-Tao Liu, Wen-Bin Guo, Jia-Yi Sun
BACKGROUND: The serum levels of Dickkopf-1 (Dkk1), a secreted Wnt family protein is changed in patients suffering various types of cancers. In the present study, we aim to explore the diagnostic value of Dkk1 as a new biomarker in breast cancer. METHODS: Serum was collected from 38 patients with breast cancer and 23 healthy controls. Serological levels of DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). Significance and diagnostic performance including receiver operator characteristic (ROC) and areas under the curve (AUC) were determined by SPSS software...
March 1, 2017: Minerva Medica
https://www.readbyqxmd.com/read/28247605/-efficacy-of-adjuvant-endocrine-therapy-in-breast-cancer-patients-with-a-positive-to-negative-switch-of-hormone-receptor-status-after-neoadjuvant-chemotherapy
#10
Guangfa Xia, Juanying Zhu, Jun Yuan, Bo Cao, Jie Tang, Yiding Chen
Objective: To evaluate the efficacy of adjuvant endocrine therapy (AET) in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy (NAC). Methods: One hundred and six patients who presented with hormone receptor (HR)-positive breast cancer at diagnosis and turned to HR-negative after NAC during December 2000 and December 2013 in Jiaxing Maternity and Child Health Care Hospital were retrospectively identified. Kaplan-Meier analysis and log-rank test were used for univariate analyses of factors related to disease free survival (DFS) and overall survival (OS)...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/28247034/genomic-characteristics-of-trastuzumab-resistant-her2-positive-metastatic-breast-cancer
#11
Mateus de Oliveira Taveira, Sheida Nabavi, Yuker Wang, Peter Tonellato, Francisco J Esteva, Lewis C Cantley, Gerburg M Wulf
PURPOSE: Resistance to trastuzumab therapy is linked to phosphoinositol 3-kinase (PI3K) pathway activation. One key downstream effector and regulator of this pathway is the mechanistic target of rapamycin (mTOR). In 2011, a phase I/II study evaluated the combination of trastuzumab and everolimus (a mTOR inhibitor) for treatment of Her2-positive metastatic breast cancer (MBC) for patients who had progressed on trastuzumab-based therapy. METHODS: We retrospectively analyzed GeneChip microarray data from 22 of 47 patients included in the study...
February 28, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28237486/targeted-inhibition-of-notch1-gene-enhances-the-killing-effects-of-paclitaxel-on-triple-negative-breast-cancer-cells
#12
Yu-Fu Zhou, Qian Sun, Ya-Jun Zhang, Geng-Ming Wang, Bin He, Tao Qi, Yan Zhou, Xing-Wang Li, Sheng Li, Lin He
OBJECTIVE: To study the influence of targeted inhibition of Notch1 gene on the killing effects of paclitaxel on triple negative breast cancer cells. METHODS: The triple negative [estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (Her2)] breast cancer cell line MDA-MB-231 and ER/PR/HER-2-positive breast cancer cell line MCF-7 were cultured, transfected with Notch1-siRNA-overexpression plasmid and blank plasmid, and treated with different concentrations of paclitaxel, and then the cell proliferation activity and apoptosis rate as well as the mRNA expression of Caspase-3, Caspase-9 and Bcl-2 were determined...
February 2017: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/28208987/bcl6-mrna-expression-level-in-invasive-duct-carcinoma-not-otherwise-specified
#13
Eman Badr, Eman Masoud, Asmaa Gaber Abdou, Marwa Serag Eldien
INTRODUCTION: B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function. AIM: To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28197225/herceptin-responsive-lung-adenocarcinoma-in-the-setting-of-bilateral-synchronous-lung-primaries-and-breast-carcinoma
#14
Gerard J Fitzmaurice, Michael Moore, Waris Ahmad, Ronan J Ryan
The incidence of human epidermal growth factor receptor 2 (Her-2) mutations in lung adenocarcinoma is approximately 3%; however, its significance in the management of these lung cancers remains under investigation. We describe an incidental but unique opportunity to evaluate the response to treatment with herceptin in a patient with bilateral synchronous lung primaries in conjunction with breast carcinoma. Interval imaging following surgical resection of the squamous cell carcinoma while on herceptin treatment delineated the radiological regression of the Her-2 positive lung adenocarcinoma...
January 2017: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/28186977/pathological-complete-response-of-her2-positive-breast-cancer-to-trastuzumab-and-chemotherapy-can-be-predicted-by-hsd17b4-methylation
#15
Satoshi Fujii, Satoshi Yamashita, Takeshi Yamaguchi, Masato Takahashi, Yasuo Hozumi, Toshikazu Ushijima, Hirofumi Mukai
Human epidermal growth factor (HER) 2-directed therapy is the standard treatment for HER2-positive breast cancer. Patients who achieved a pathological complete response (pCR) to the therapy are associated with excellent disease-free survival. However, few molecular markers are available to predict pCR. Here, we aimed to establish a DNA methylation marker to predict the response to trastuzumab and chemotherapy. A total of 67 patients were divided into screening (n = 21) and validation (n = 46) sets. Genome-wide DNA methylation analysis of the screening set identified eight genomic regions specifically methylated in patients with pCR...
February 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28178676/lymph-node-status-in-different-molecular-subtype-of-breast-cancer-triple-negative-tumours-are-more-likely-lymph-node-negative
#16
Ning Liu, Zhigang Yang, Xiaozhen Liu, Yun Niu
BACKGROUND AND OBJECTIVES: To investigate the association between different molecular subtype(MST) and the axillary lymph nodal(ALN) status. METHODS: A total of 528 female patients with primary breast cancer were collected. Survival estimates were calculated using the Kaplan-Meier method, univariate and multivariate logistic regression models. RESULTS: Triple negative and Luminal A breast cancers were more frequently node-negative(N0) when compared to Luminal B and Her-2 positive cancers (77...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28152863/breast-oncology-precision-medicine-genomic-testing-and-treatment-at-the-population-level
#17
Yun Li, Allison W Kurian, Steven J Katz
288 Background: The 21-gene assay used to estimate breast cancer recurrence and tailor chemotherapy (chemo) receipt has demonstrated predictive validity and clinical utility. Yet it is unclear how involved patients are in the decision to perform the test, or how oncologists use results to recommend systemic chemo. We examined the patient experience with assay testing, physician recommendations, and chemo receipt based on test results. METHODS: The iCanCare study surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer who were treated in 2013-14, identified through the population-based SEER registries of Los Angeles and Georgia about 3 months after surgical treatment, and merged with SEER data (N=2632, RR=70%)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152547/neratinib-resistance-and-cross-resistance-to-other-her2-targeted-drugs-due-to-increased-activity-of-metabolism-enzyme-cytochrome-p4503a4
#18
Susan Breslin, Michelle C Lowry, Lorraine O'Driscoll
BACKGROUND: Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the potential mechanism of this resistance. METHODS: Neratinib-resistant variants of HER2-positive breast cancer cells were developed and their cross-resistance investigated using cytotoxicity assays. Similarly, sensitivity of trastuzumab-resistant and lapatinib-resistant cells to neratinib was assessed...
February 28, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28130113/exploring-the-pharmacological-mechanism-of-yanghe-decoction-on-her2-positive-breast-cancer-by-a-network-pharmacology-approach
#19
Liuting Zeng, Kailin Yang
ETHNOPHARMACOLOGICAL RELEVANCE: Certain Chinese medicine formulae from traditional Chinese Medicine (TCM) are effective for treating and preventing diseases in clinical practice. Yanghe Decoction (YHD) is a Chinese medicine formula that is used to treat breast cancer, especially HER-positive breast cancer; however, the active compounds, potential targets, and pharmacological and molecular mechanism of its action against cancer remain unclear. Therefore, further investigation is required...
January 24, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28109404/how-could-breast-cancer-molecular-features-contribute-to-locoregional-treatment-decision-making
#20
REVIEW
Pelagia G Tsoutsou, Marie-Catherine Vozenin, André-Dante Durham, Jean Bourhis
Systemic treatments are tailored to breast cancer (BC) heterogeneity, which is not yet taken into account for radiotherapy (RT) personalization. The primary objective of this review is to summarize existing data suggesting BC subtypes and genetic assays are prognostic and predictive biomarkers useful for RT decision-making and to provide implications for their incorporation into future translational and clinical research. The evidence suggesting that BC subtypes also exhibit distinct "locoregional recurrence (LRR)" patterns is retrospective but consistent and validated in over fifteen studies...
February 2017: Critical Reviews in Oncology/hematology
keyword
keyword
36131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"